Moderna beats quarterly revenue estimates on COVID vaccine strength

Moderna beat Wall Street estimates for second-quarter revenue on Friday benefiting from better-than-expected sales of its COVID-19 vaccine, as the company gears up for the potential launch of its flu shot.